SI3892295T1 - Individualizirana cepiva proti raku - Google Patents
Individualizirana cepiva proti rakuInfo
- Publication number
- SI3892295T1 SI3892295T1 SI201232029T SI201232029T SI3892295T1 SI 3892295 T1 SI3892295 T1 SI 3892295T1 SI 201232029 T SI201232029 T SI 201232029T SI 201232029 T SI201232029 T SI 201232029T SI 3892295 T1 SI3892295 T1 SI 3892295T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cancer
- individualized vaccines
- individualized
- vaccines
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/70—Machine learning, data mining or chemometrics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/002576 WO2012159643A1 (en) | 2011-05-24 | 2011-05-24 | Individualized vaccines for cancer |
EP2012000006 | 2012-01-02 | ||
EP21168360.2A EP3892295B1 (en) | 2011-05-24 | 2012-05-23 | Individualized vaccines for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3892295T1 true SI3892295T1 (sl) | 2023-09-29 |
Family
ID=46148823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231954T SI3473267T1 (sl) | 2011-05-24 | 2012-05-23 | Individualizirana cepiva za rak |
SI201232029T SI3892295T1 (sl) | 2011-05-24 | 2012-05-23 | Individualizirana cepiva proti raku |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231954T SI3473267T1 (sl) | 2011-05-24 | 2012-05-23 | Individualizirana cepiva za rak |
Country Status (22)
Country | Link |
---|---|
US (3) | US10738355B2 (sl) |
JP (5) | JP6444171B2 (sl) |
CN (3) | CN103608033B (sl) |
AU (4) | AU2012261237B2 (sl) |
BR (1) | BR112013029834A8 (sl) |
CA (1) | CA2836494C (sl) |
DK (2) | DK2714071T3 (sl) |
ES (3) | ES2746233T3 (sl) |
FI (1) | FI3892295T3 (sl) |
HR (2) | HRP20230443T1 (sl) |
HU (3) | HUE062102T2 (sl) |
LT (3) | LT3892295T (sl) |
MX (2) | MX360823B (sl) |
NZ (2) | NZ742420A (sl) |
PL (1) | PL3892295T3 (sl) |
PT (3) | PT3473267T (sl) |
RS (2) | RS62497B1 (sl) |
RU (1) | RU2670745C9 (sl) |
SG (2) | SG193553A1 (sl) |
SI (2) | SI3473267T1 (sl) |
WO (1) | WO2012159754A2 (sl) |
ZA (1) | ZA201306944B (sl) |
Families Citing this family (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
CN104195227B (zh) | 2008-11-07 | 2017-04-12 | 适应生物技术公司 | 通过序列分析监测状况的方法 |
EP2387627B1 (en) | 2009-01-15 | 2016-03-30 | Adaptive Biotechnologies Corporation | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
RU2539032C2 (ru) | 2009-06-25 | 2015-01-10 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ измерения искусственного иммунитета |
US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CA2813466A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
SG193553A1 (en) | 2011-05-24 | 2013-10-30 | Biontech Ag | Individualized vaccines for cancer |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
AU2012325791B2 (en) | 2011-10-21 | 2018-04-05 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
CA2858070C (en) | 2011-12-09 | 2018-07-10 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
SG11201405274WA (en) | 2012-02-27 | 2014-10-30 | Cellular Res Inc | Compositions and kits for molecular counting |
ES2662128T3 (es) | 2012-03-05 | 2018-04-05 | Adaptive Biotechnologies Corporation | Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes |
EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
ES2582554T3 (es) | 2012-05-08 | 2016-09-13 | Adaptive Biotechnologies Corporation | Composiciones y método para medir y calibrar el sesgo de la amplificación en reacciones de PCR multiplexadas |
EP2872653B1 (en) * | 2012-07-12 | 2019-03-13 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
US10501801B2 (en) | 2012-09-28 | 2019-12-10 | University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
CA2886647A1 (en) | 2012-10-01 | 2014-04-10 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
CA2892391C (en) * | 2012-11-28 | 2023-10-17 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
WO2014093186A1 (en) * | 2012-12-12 | 2014-06-19 | Garvin Alex M | Non-invasive detection of colorectal neoplasia using circular consensus sequencing |
EP2946345B1 (en) | 2013-01-17 | 2024-04-03 | Personalis, Inc. | Methods and systems for genetic analysis |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
JP6431895B2 (ja) * | 2013-03-15 | 2018-12-05 | アダプティブ バイオテクノロジーズ コーポレイション | 複合遺伝子セットにおいてユニークにタグ付けされた再構成された適応免疫受容体遺伝子 |
AU2014251207B2 (en) * | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
US20160186260A1 (en) * | 2013-07-26 | 2016-06-30 | Sequenta, Llc | Cancer vaccination with antigen evolution |
SG10201806890VA (en) | 2013-08-28 | 2018-09-27 | Cellular Res Inc | Massively parallel single cell analysis |
EP3039161B1 (en) | 2013-08-30 | 2021-10-06 | Personalis, Inc. | Methods and systems for genomic analysis |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051275A1 (en) | 2013-10-03 | 2015-04-09 | Personalis, Inc. | Methods for analyzing genotypes |
US9582877B2 (en) | 2013-10-07 | 2017-02-28 | Cellular Research, Inc. | Methods and systems for digitally counting features on arrays |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
ES2693217T3 (es) * | 2013-12-02 | 2018-12-10 | Personal Genome Diagnostics Inc. | Método para evaluar variantes minoritarias en una muestra |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
NZ721105A (en) * | 2013-12-06 | 2022-04-29 | Broad Inst Inc | Formulations for neoplasia vaccines |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
CA2941612A1 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
ES2777529T3 (es) | 2014-04-17 | 2020-08-05 | Adaptive Biotechnologies Corp | Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células |
EP3981437A1 (en) | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
US10564165B2 (en) | 2014-09-10 | 2020-02-18 | Genentech, Inc. | Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information |
US10973894B2 (en) | 2014-10-02 | 2021-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
US10392663B2 (en) | 2014-10-29 | 2019-08-27 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples |
EP4026913A1 (en) | 2014-10-30 | 2022-07-13 | Personalis, Inc. | Methods for using mosaicism in nucleic acids sampled distal to their origin |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
EP3224384A4 (en) | 2014-11-25 | 2018-04-18 | Adaptive Biotechnologies Corp. | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
ES2824700T3 (es) * | 2015-02-19 | 2021-05-13 | Becton Dickinson Co | Análisis unicelular de alto rendimiento que combina información proteómica y genómica |
ES2858306T3 (es) | 2015-02-24 | 2021-09-30 | Adaptive Biotechnologies Corp | Método para determinar el estado de HLA mediante secuenciación del repertorio inmunitario |
EP3261605B2 (en) | 2015-02-26 | 2022-04-20 | SiO2 Medical Products, Inc. | Cycloolefin polymer container with a scratch resistant and anti-static coating |
US9727810B2 (en) | 2015-02-27 | 2017-08-08 | Cellular Research, Inc. | Spatially addressable molecular barcoding |
EP3277843A2 (en) | 2015-03-30 | 2018-02-07 | Cellular Research, Inc. | Methods and compositions for combinatorial barcoding |
WO2016161273A1 (en) | 2015-04-01 | 2016-10-06 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
CN107580632B (zh) | 2015-04-23 | 2021-12-28 | 贝克顿迪金森公司 | 用于全转录组扩增的方法和组合物 |
IL298497A (en) * | 2015-04-27 | 2023-01-01 | Cancer Research Tech Ltd | A method for treating cancer |
AU2016260540B2 (en) * | 2015-05-13 | 2021-01-07 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
IL255769B2 (en) | 2015-05-20 | 2023-09-01 | Broad Inst Inc | shared neoantigens |
WO2016196229A1 (en) | 2015-06-01 | 2016-12-08 | Cellular Research, Inc. | Methods for rna quantification |
TW202241500A (zh) * | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
WO2017020026A1 (en) * | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
WO2017044574A1 (en) | 2015-09-11 | 2017-03-16 | Cellular Research, Inc. | Methods and compositions for nucleic acid library normalization |
EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
WO2017066256A2 (en) * | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
CA3003304A1 (en) * | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Viral neoepitopes and uses thereof |
CN114404581A (zh) * | 2015-10-22 | 2022-04-29 | 摩登纳特斯有限公司 | 癌症疫苗 |
PE20181535A1 (es) | 2015-12-16 | 2018-09-26 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno |
CN105349533A (zh) * | 2015-12-21 | 2016-02-24 | 生工生物工程(上海)股份有限公司 | 构建链特异性转录组文库的方法 |
US20190022202A1 (en) * | 2016-01-08 | 2019-01-24 | Vaccibody As | Therapeutic anticancer neoepitope vaccine |
EP3400005A1 (en) * | 2016-01-08 | 2018-11-14 | Vaccibody AS | Neoepitope rna cancer vaccine |
WO2017222619A2 (en) | 2016-03-24 | 2017-12-28 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
EP3777881A1 (en) * | 2016-04-22 | 2021-02-17 | CureVac AG | Rna encoding a tumor antigen |
US10822643B2 (en) | 2016-05-02 | 2020-11-03 | Cellular Research, Inc. | Accurate molecular barcoding |
CA3022924A1 (en) * | 2016-05-04 | 2017-11-09 | Immunovaccine Technologies Inc. | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof |
US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
CN109074430B (zh) | 2016-05-26 | 2022-03-29 | 贝克顿迪金森公司 | 分子标记计数调整方法 |
WO2017205810A1 (en) * | 2016-05-27 | 2017-11-30 | Etubics Corporation | Neoepitope vaccine compositions and methods of use thereof |
US11299783B2 (en) | 2016-05-27 | 2022-04-12 | Personalis, Inc. | Methods and systems for genetic analysis |
US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
WO2018011289A1 (en) * | 2016-07-13 | 2018-01-18 | Vaximm Ag | Process for the production of a dna vaccine for cancer immunotherapy |
RS62390B1 (sr) * | 2016-07-20 | 2021-10-29 | BioNTech SE | Izbor neoepitopa kao ciljeva specifičnih za bolest za terapiju sa povećanom efikasnošću |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
WO2018058073A2 (en) | 2016-09-26 | 2018-03-29 | Cellular Research, Inc. | Measurement of protein expression using reagents with barcoded oligonucleotide sequences |
KR20190077061A (ko) | 2016-11-08 | 2019-07-02 | 셀룰러 리서치, 인크. | 세포 표지 분류 방법 |
EP3539035B1 (en) | 2016-11-08 | 2024-04-17 | Becton, Dickinson and Company | Methods for expression profile classification |
WO2018089637A1 (en) | 2016-11-11 | 2018-05-17 | Nantbio, Inc. | Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms |
CN108090325B (zh) * | 2016-11-23 | 2022-01-25 | 中国科学院昆明动物研究所 | 一种应用β-稳定性分析单细胞测序数据的方法 |
JP7104048B2 (ja) | 2017-01-13 | 2022-07-20 | セルラー リサーチ, インコーポレイテッド | 流体チャネルの親水性コーティング |
US20190369096A1 (en) * | 2017-01-13 | 2019-12-05 | Nantbio, Inc. | Validation of neoepitope-based treatment |
EP3576781B9 (en) * | 2017-01-18 | 2024-03-06 | Icahn School of Medicine at Mount Sinai | Neoantigens and uses thereof for treating cancer |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
RU2768829C2 (ru) * | 2017-02-01 | 2022-03-24 | МОДЕРНАТиЭкс, ИНК. | Противораковые рнк-вакцины |
CN110382708A (zh) | 2017-02-01 | 2019-10-25 | 赛卢拉研究公司 | 使用阻断性寡核苷酸进行选择性扩增 |
CN117224710A (zh) * | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
ES2965475T3 (es) | 2017-02-12 | 2024-04-15 | Biontech Us Inc | Métodos y composiciones basados en HLA y usos de los mismos |
CN110582280B (zh) | 2017-03-31 | 2024-03-19 | 小利兰·斯坦福大学托管委员会 | 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法 |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
EP3615675A4 (en) | 2017-04-24 | 2021-03-03 | Nantcell, Inc. | TARGETED NEOEPITOP VECTORS AND METHOD FOR THEREFORE |
CN110612116A (zh) | 2017-05-08 | 2019-12-24 | 磨石肿瘤生物技术公司 | 甲病毒新抗原载体 |
US11464798B2 (en) | 2017-05-11 | 2022-10-11 | Theralase Technologies Inc. | Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same |
CA3059559A1 (en) | 2017-06-05 | 2018-12-13 | Becton, Dickinson And Company | Sample indexing for single cells |
WO2018224166A1 (en) * | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
US20200230220A1 (en) | 2017-07-12 | 2020-07-23 | Nouscom Ag | Neoantigen vaccine composition for treatment of cancer |
US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS |
JP2021503897A (ja) * | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
US20200354730A1 (en) * | 2017-11-27 | 2020-11-12 | Nantcell, Inc. | Improved Yeast Polytope Vaccine Compositions And Methods |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
US20200368336A1 (en) * | 2017-12-01 | 2020-11-26 | Shanghai Jenomed Biotech Co., Ltd. | Method for preparing personalized cancer vaccine |
WO2019125864A1 (en) * | 2017-12-18 | 2019-06-27 | Personal Genome Diagnostics Inc. | Machine learning system and method for somatic mutation discovery |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
EP3728636A1 (en) | 2017-12-19 | 2020-10-28 | Becton, Dickinson and Company | Particles associated with oligonucleotides |
MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
JP7437310B2 (ja) * | 2018-03-14 | 2024-02-22 | コーニンクレッカ フィリップス エヌ ヴェ | Rnaシーケンシングデータの転写発現レベルを解釈するために局所的なユニークな特徴を使用するシステム及び方法 |
US11065317B2 (en) | 2018-04-26 | 2021-07-20 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
US11773441B2 (en) | 2018-05-03 | 2023-10-03 | Becton, Dickinson And Company | High throughput multiomics sample analysis |
JP7358388B2 (ja) | 2018-05-03 | 2023-10-10 | ベクトン・ディキンソン・アンド・カンパニー | 反対側の転写物末端における分子バーコーディング |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neo-antigens |
KR20210018321A (ko) * | 2018-05-25 | 2021-02-17 | 더 위스타 인스티튜트 | 종양 특이적 신생항원 및 이를 사용하는 방법 |
CN108897986B (zh) * | 2018-05-29 | 2020-11-27 | 中南大学 | 一种基于蛋白质信息的基因组序列拼接方法 |
US11814750B2 (en) | 2018-05-31 | 2023-11-14 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
US10801064B2 (en) | 2018-05-31 | 2020-10-13 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
WO2020006242A1 (en) * | 2018-06-27 | 2020-01-02 | Modernatx, Inc. | Personalized cancer vaccine epitope selection |
US11639517B2 (en) | 2018-10-01 | 2023-05-02 | Becton, Dickinson And Company | Determining 5′ transcript sequences |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
CN114573688A (zh) * | 2018-10-19 | 2022-06-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
AU2019374818A1 (en) * | 2018-11-07 | 2021-05-27 | Modernatx, Inc. | RNA cancer vaccines |
US11932849B2 (en) | 2018-11-08 | 2024-03-19 | Becton, Dickinson And Company | Whole transcriptome analysis of single cells using random priming |
EP3881324A1 (en) * | 2018-11-15 | 2021-09-22 | Nouscom AG | Selection of cancer mutations for generation of a personalized cancer vaccine |
EP3894552A1 (en) | 2018-12-13 | 2021-10-20 | Becton, Dickinson and Company | Selective extension in single cell whole transcriptome analysis |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
CA3124457A1 (en) | 2018-12-21 | 2020-06-25 | Biontech Us Inc. | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
US11371076B2 (en) | 2019-01-16 | 2022-06-28 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
EP3914728B1 (en) | 2019-01-23 | 2023-04-05 | Becton, Dickinson and Company | Oligonucleotides associated with antibodies |
JP2022519649A (ja) | 2019-02-08 | 2022-03-24 | ジェネンテック, インコーポレイテッド | がんの診断および治療方法 |
US20220160850A1 (en) * | 2019-02-15 | 2022-05-26 | Rjan Holding Ab | Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine |
US20220154180A1 (en) | 2019-03-13 | 2022-05-19 | Toyobo Co., Ltd. | Production and amplification of nucleic acids |
US11965208B2 (en) | 2019-04-19 | 2024-04-23 | Becton, Dickinson And Company | Methods of associating phenotypical data and single cell sequencing data |
BR122024002387A2 (pt) | 2019-05-30 | 2024-03-12 | Gritstone Bio, Inc. | Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral |
US11939622B2 (en) | 2019-07-22 | 2024-03-26 | Becton, Dickinson And Company | Single cell chromatin immunoprecipitation sequencing assay |
CN110277135B (zh) * | 2019-08-10 | 2021-06-01 | 杭州新范式生物医药科技有限公司 | 一种基于预期疗效选择个体化肿瘤新抗原的方法和系统 |
CN114502781A (zh) * | 2019-09-20 | 2022-05-13 | 纳维再生科技股份有限公司 | 个人化癌症免疫治疗 |
CN114729350A (zh) | 2019-11-08 | 2022-07-08 | 贝克顿迪金森公司 | 使用随机引发获得用于免疫组库测序的全长v(d)j信息 |
CN112795647B (zh) * | 2019-11-14 | 2022-08-16 | 北京肿瘤医院(北京大学肿瘤医院) | 一种肿瘤标志物及其应用 |
CR20230210A (es) | 2019-12-13 | 2023-06-14 | Genentech Inc | ANTICUERPOS ANTI-LY6G6D Y MÉTODOS DE USO (Divisional 2022-0330) |
WO2021146207A1 (en) | 2020-01-13 | 2021-07-22 | Becton, Dickinson And Company | Methods and compositions for quantitation of proteins and rna |
EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
AU2021236763A1 (en) | 2020-03-20 | 2022-10-06 | Lonza Sales Ag | Extracellular vesicles for therapy |
US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
WO2021231779A1 (en) | 2020-05-14 | 2021-11-18 | Becton, Dickinson And Company | Primers for immune repertoire profiling |
KR20230029673A (ko) | 2020-05-26 | 2023-03-03 | 디오니스 테라퓨틱스, 아이엔씨. | 핵산 인공 미니-프로테옴 라이브러리 |
US11932901B2 (en) | 2020-07-13 | 2024-03-19 | Becton, Dickinson And Company | Target enrichment using nucleic acid probes for scRNAseq |
AU2021320896A1 (en) | 2020-08-06 | 2023-03-23 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP4216993A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
CN116635533A (zh) | 2020-11-20 | 2023-08-22 | 贝克顿迪金森公司 | 高表达的蛋白和低表达的蛋白的谱分析 |
US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
AU2021400424A1 (en) | 2020-12-14 | 2023-07-06 | Biontech Us Inc. | Tissue-specific antigens for cancer immunotherapy |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
CA3227081A1 (en) | 2021-08-24 | 2023-03-02 | Irena RABE | In vitro transcription technologies |
WO2023076733A1 (en) | 2021-11-01 | 2023-05-04 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
CN114181287B (zh) * | 2021-12-10 | 2023-09-19 | 商丘美兰生物工程有限公司 | 一种dna病毒疫苗的制备方法 |
CN114410778B (zh) * | 2021-12-29 | 2024-03-19 | 中南大学湘雅医院 | Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用 |
CN114350800B (zh) * | 2021-12-29 | 2024-03-19 | 中南大学湘雅医院 | Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用 |
KR20230130804A (ko) * | 2022-03-04 | 2023-09-12 | (주)큐리진 | 순환종양세포 검출을 위한 아데노바이러스 5/3 형 |
EP4253550A1 (en) | 2022-04-01 | 2023-10-04 | GenCC GmbH 6 Co. KG | Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes |
WO2023209068A1 (en) | 2022-04-28 | 2023-11-02 | Carbocalyx Gmbh | Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
WO2024063788A1 (en) * | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064931A1 (en) * | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
DE69714033T2 (de) * | 1996-04-19 | 2003-02-13 | Us Gov Nat Inst Health | Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten |
WO1997041440A1 (en) | 1996-04-26 | 1997-11-06 | Rijksuniversiteit Te Leiden | Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes |
KR100507660B1 (ko) | 1996-09-13 | 2005-08-10 | 리폭센 테크놀로지즈 리미티드 | 리포좀 |
WO1998016238A2 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
BR9813981A (pt) | 1997-11-06 | 2000-09-26 | Roche Diagnostics Gmbh | Antìgenos de tumor especìficos, métodos para a sua produção e seu uso imunização de diagnóstico |
WO1999034014A2 (en) | 1997-12-23 | 1999-07-08 | Roche Diagnostics Gmbh | A method for the determination of a nucleic acid |
AU1774299A (en) * | 1997-12-24 | 1999-07-19 | Imperial Cancer Research Technology Limited | Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
EP1117430A1 (en) | 1998-10-05 | 2001-07-25 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
KR100773109B1 (ko) | 1999-05-06 | 2007-11-02 | 웨이크 포리스트 유니버시티 | 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법 |
JP2003509035A (ja) | 1999-09-16 | 2003-03-11 | ザイコス インク. | ポリエピトープポリペプチドをコードする核酸 |
AU784605B2 (en) * | 1999-10-20 | 2006-05-11 | Johns Hopkins University School Of Medicine, The | Chimeric immunogenic compositions and nucleic acids encoding them |
AU4903101A (en) | 1999-11-30 | 2001-07-09 | Cornell Research Foundation Inc. | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
EP1242108B1 (en) | 1999-12-28 | 2007-07-11 | Pharmexa Inc. | Optimized minigenes and peptides encoded thereby |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
US20040052763A1 (en) | 2000-06-07 | 2004-03-18 | Mond James J. | Immunostimulatory RNA/DNA hybrid molecules |
AU2001278117A1 (en) | 2000-08-03 | 2002-02-18 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
CN100392087C (zh) | 2001-11-26 | 2008-06-04 | 昆士兰大学 | 黄病毒疫苗输送系统 |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
WO2003070162A2 (en) * | 2002-02-19 | 2003-08-28 | Genzyme Corporation | Par-3 compounds for therapy and diagnosis and methods for using same |
WO2003078595A2 (en) * | 2002-03-15 | 2003-09-25 | Astral, Inc. | Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
AU2003245942B2 (en) | 2002-06-13 | 2008-07-24 | Merck Patent Gmbh | Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
CA2542217C (en) | 2003-10-15 | 2018-03-27 | Medigene Ag | Method of administering cationic liposomes comprising an active drug |
JP4931593B2 (ja) | 2003-10-24 | 2012-05-16 | イミュネイド ピーティーワイ リミテッド | 治療の方法 |
EP1589030A1 (en) * | 2004-04-14 | 2005-10-26 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Bob-1 specific T cells and methods to use |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
JP2008526764A (ja) | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 免疫応答の誘導におけるcd4+細胞の回避方法 |
AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
EP4174179A3 (en) | 2005-08-23 | 2023-09-27 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
WO2007101227A2 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
JP2009529878A (ja) | 2006-03-13 | 2009-08-27 | ベリデックス・エルエルシー | 原発細胞の増殖 |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
EP2061504A4 (en) | 2006-09-20 | 2010-01-27 | Univ Johns Hopkins | COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES |
DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
NZ704295A (en) | 2006-12-27 | 2016-06-24 | Harvard College | Compositions and methods for the treatment of infections and tumors |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
CA2719544C (en) | 2008-03-24 | 2018-01-09 | 4Sc Ag | Substituted imidazoquinolines |
WO2009129227A1 (en) | 2008-04-17 | 2009-10-22 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
JP5268444B2 (ja) * | 2008-06-23 | 2013-08-21 | 株式会社日立ハイテクノロジーズ | 単分子リアルタイムシーケンス装置,核酸分析装置及び単分子リアルタイムシーケンス方法 |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
EP2344192A4 (en) | 2008-10-11 | 2013-02-13 | Government Of The Usa As Represented By The Secretary Dept Of Health And Human Services | METHOD FOR MANUFACTURING A VACCINE |
AU2009319701B2 (en) | 2008-11-28 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods for the treatment of infections and tumors |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
DK2459231T3 (en) | 2009-07-31 | 2016-09-05 | Ethris Gmbh | RNA with a combination of unmodified and modified nucleotides for protein expression |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
EP3023788B1 (en) | 2010-05-14 | 2020-02-12 | The General Hospital Corporation | Compositions of tumor specific neoantigens for use in treating tumours |
CA2813466A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
DE102011102734A1 (de) | 2011-05-20 | 2012-11-22 | WMF Württembergische Metallwarenfabrik Aktiengesellschaft | Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch |
EP3473267B1 (en) | 2011-05-24 | 2021-09-08 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
SG193553A1 (en) | 2011-05-24 | 2013-10-30 | Biontech Ag | Individualized vaccines for cancer |
EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
CN110511939A (zh) | 2011-10-03 | 2019-11-29 | 现代泰克斯公司 | 修饰的核苷、核苷酸和核酸及其用途 |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US20150030576A1 (en) | 2012-01-10 | 2015-01-29 | Moderna Therapeutics, Inc. | Methods and compositions for targeting agents into and across the blood-brain barrier |
EP2817322B1 (en) | 2012-02-20 | 2016-04-20 | Universita' degli Studi di Milano | Homo- and heterodimeric smac mimetic compounds as apoptosis inducers |
US20130255281A1 (en) | 2012-03-29 | 2013-10-03 | General Electric Company | System and method for cooling electrical components |
EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
EP2872653B1 (en) | 2012-07-12 | 2019-03-13 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
JP6510416B2 (ja) | 2012-11-01 | 2019-05-08 | ファクター バイオサイエンス インコーポレイテッド | 細胞中でタンパク質を発現するための方法および生成物 |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
EP3578652B1 (en) | 2013-03-15 | 2023-07-12 | ModernaTX, Inc. | Ribonucleic acid purification |
EP3578663A1 (en) | 2013-03-15 | 2019-12-11 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
AU2014251207B2 (en) | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
JP2016530294A (ja) | 2013-09-03 | 2016-09-29 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | キメラポリヌクレオチド |
EP3043826A4 (en) | 2013-09-13 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
US9950065B2 (en) | 2013-09-26 | 2018-04-24 | Biontech Rna Pharmaceuticals Gmbh | Particles comprising a shell with RNA |
WO2015051173A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc | Polynucleotide molecules and uses thereof |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
EP3076994A4 (en) | 2013-12-06 | 2017-06-07 | Modernatx, Inc. | Targeted adaptive vaccines |
US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
CA2938700A1 (en) | 2014-02-05 | 2015-08-13 | Biontech Ag | A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device |
EP3981437A1 (en) | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
EP3708668B1 (en) | 2014-12-12 | 2022-07-27 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
MX2017008670A (es) | 2014-12-30 | 2017-10-11 | Curevac Ag | Moleculas artificiales de acido nucleico novedosas. |
WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
-
2012
- 2012-05-23 SG SG2013070727A patent/SG193553A1/en unknown
- 2012-05-23 RS RS20211268A patent/RS62497B1/sr unknown
- 2012-05-23 SI SI201231954T patent/SI3473267T1/sl unknown
- 2012-05-23 LT LTEP21168360.2T patent/LT3892295T/lt unknown
- 2012-05-23 HU HUE21168360A patent/HUE062102T2/hu unknown
- 2012-05-23 HR HRP20230443TT patent/HRP20230443T1/hr unknown
- 2012-05-23 WO PCT/EP2012/002209 patent/WO2012159754A2/en active Application Filing
- 2012-05-23 HU HUE18199105A patent/HUE057608T2/hu unknown
- 2012-05-23 HR HRP20211595TT patent/HRP20211595T1/hr unknown
- 2012-05-23 LT LTEP18199105.0T patent/LT3473267T/lt unknown
- 2012-05-23 DK DK12723117.3T patent/DK2714071T3/da active
- 2012-05-23 HU HUE12723117A patent/HUE046152T2/hu unknown
- 2012-05-23 US US14/119,348 patent/US10738355B2/en active Active
- 2012-05-23 NZ NZ742420A patent/NZ742420A/en unknown
- 2012-05-23 CN CN201280029551.XA patent/CN103608033B/zh active Active
- 2012-05-23 AU AU2012261237A patent/AU2012261237B2/en active Active
- 2012-05-23 DK DK21168360.2T patent/DK3892295T3/da active
- 2012-05-23 CN CN202010087649.7A patent/CN111286537A/zh active Pending
- 2012-05-23 JP JP2014511773A patent/JP6444171B2/ja active Active
- 2012-05-23 ES ES12723117T patent/ES2746233T3/es active Active
- 2012-05-23 LT LTEP12723117.3T patent/LT2714071T/lt unknown
- 2012-05-23 CN CN201610330937.4A patent/CN105999250B/zh active Active
- 2012-05-23 ES ES18199105T patent/ES2897656T3/es active Active
- 2012-05-23 RS RS20230380A patent/RS64230B1/sr unknown
- 2012-05-23 PL PL21168360.2T patent/PL3892295T3/pl unknown
- 2012-05-23 ES ES21168360T patent/ES2946072T3/es active Active
- 2012-05-23 FI FIEP21168360.2T patent/FI3892295T3/fi active
- 2012-05-23 BR BR112013029834A patent/BR112013029834A8/pt not_active Application Discontinuation
- 2012-05-23 CA CA2836494A patent/CA2836494C/en active Active
- 2012-05-23 PT PT181991050T patent/PT3473267T/pt unknown
- 2012-05-23 RU RU2013157150A patent/RU2670745C9/ru active
- 2012-05-23 SG SG10201911616QA patent/SG10201911616QA/en unknown
- 2012-05-23 PT PT211683602T patent/PT3892295T/pt unknown
- 2012-05-23 MX MX2013013659A patent/MX360823B/es active IP Right Grant
- 2012-05-23 NZ NZ730355A patent/NZ730355A/en unknown
- 2012-05-23 SI SI201232029T patent/SI3892295T1/sl unknown
- 2012-05-23 PT PT12723117T patent/PT2714071T/pt unknown
-
2013
- 2013-09-16 ZA ZA2013/06944A patent/ZA201306944B/en unknown
- 2013-11-22 MX MX2020011767A patent/MX2020011767A/es unknown
-
2016
- 2016-09-05 JP JP2016172519A patent/JP6456888B2/ja active Active
-
2017
- 2017-08-10 AU AU2017213515A patent/AU2017213515B2/en active Active
-
2018
- 2018-12-19 JP JP2018237242A patent/JP2019050831A/ja active Pending
-
2019
- 2019-09-13 AU AU2019229434A patent/AU2019229434B2/en active Active
-
2020
- 2020-05-22 JP JP2020089657A patent/JP7297715B2/ja active Active
- 2020-07-02 US US16/920,286 patent/US11248264B2/en active Active
-
2022
- 2022-01-14 US US17/576,170 patent/US20220282322A1/en active Pending
- 2022-02-24 AU AU2022201275A patent/AU2022201275A1/en active Pending
-
2023
- 2023-03-22 JP JP2023045776A patent/JP2023083289A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201306944B (en) | Individualized vaccines for cancer | |
HK1197182A1 (en) | Cancer immunotherapy | |
EP2714073A4 (en) | ANTI-CANCER ANTIGEN GENE VACCINE IN SITU | |
PL2758630T3 (pl) | Regulowany system do szczelinowania | |
HK1199448A1 (en) | Disubstituted 5-fluoro-pyrimidines 5-- | |
IL231043A0 (en) | vaccine | |
GB201120860D0 (en) | Cancer immunotherapy | |
GB201119999D0 (en) | Vaccine | |
HK1201176A1 (en) | Antigen presenting cancer vaccine | |
EP2763699A4 (en) | VACCINE | |
HK1202070A1 (en) | Vaccine for tumor immunotherapy | |
ZA201306245B (en) | Combination vaccines | |
EP2771453A4 (en) | DIATOM-BASED VACCINES | |
RS59369B1 (sr) | Individualizovane vakcine protiv kancera | |
PL2729158T3 (pl) | Szczepionki przeciwko Chlamydia | |
GB201120000D0 (en) | Vaccine | |
GB201107549D0 (en) | Cancer vaccine | |
GB201108984D0 (en) | Vaccines | |
GB201108986D0 (en) | Vaccines | |
GB201108982D0 (en) | Vaccines | |
GB201121647D0 (en) | Vaccine | |
GB201108256D0 (en) | Vaccine |